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Abstract
Background: Neramexane is a new substance that exhibits antagonistic properties at a9a10 cholinergic nicotinic
receptors and N-methyl-D-aspartate receptors, suggesting potential efficacy in the treatment of tinnitus.
Methods: A total of 431 outpatients with moderate to severe subjective tinnitus (onset 3-18 months before
screening) were assigned randomly to receive either placebo or neramexane mesylate (25 mg/day, 50 mg/day and
75 mg/day) for 16 weeks, with assessment at 4-week intervals. The primary (intention-to-treat) efficacy analysis was
based on the change from baseline in Week 16 in the total score of the adapted German short version of the
validated Tinnitus Handicap Inventory questionnaire (THI-12).
Results: Compared with placebo, the largest improvement was achieved in the 50 mg/d neramexane group,
followed by the 75 mg/d neramexane group. This treatment difference did not reach statistical significance at the
pre-defined endpoint in Week 16 (p = 0.098 for 50 mg/d; p = 0.289 for 75 mg/d neramexane), but consistent
numerical superiority of both neramexane groups compared with placebo was observed. Four weeks after the end
of treatment, THI-12 scores in the 50 mg/d group were significantly better than those of the controls. Secondary
efficacy variables supported this trend, with p values of < 0.05 for the 50 mg/d neramexane group associated with
the functional-communicational subscores of the THI-12 and the assessments of tinnitus annoyance and tinnitus
impact on life as measured on an 11-point Likert-like scale. No relevant changes were observed for puretone
threshold, for tinnitus pitch and loudness match, or for minimum masking levels. The 25 mg/d neramexane group
did not differ from placebo. Neramexane was generally well tolerated and had no relevant influence on laboratory
values, electrocardiography and vital signs. Dizziness was the most common adverse event and showed a clear
dose-dependence.
Conclusions: This study demonstrated the safety and tolerability of neramexane treatment in patients with
moderate to severe tinnitus. The primary efficacy variable showed a trend towards improvement of tinnitus
suffering in the medium- and high-dose neramexane groups. This finding is in line with consistent beneficial
effects observed in secondary assessment variables. These results allow appropriate dose selection for further
studies.
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Subjective tinnitus is commonly referred to as any
sound experienced by a patient without recognizable
source. It can be heard by most persons in absolute
quietness. Intermittent tinnitus not in quietness, for per-
iods of minutes or even hours, is also very common,
occurring in about 10% of the population. Even persis-
tent chronic tinnitus is not uncommon, in particular in
elderly and hearing-handicapped individuals. A large-
scale survey of the Deutsche Tinnitusliga (German Tin-
nitus Society) conducted in 1998 revealed that 4% of the
German population suffers from tinnitus [1]. Up to 36%
of patients in this survey additionally reported somato-
form symptoms such as sleeping disturbances, depres-
sion and others, making tinnitus a severe burden for
their daily life.
Although the pathophysiology of subjective tinnitus is
poorly understood, and a definitive pathogenesis is
unknown, both acetylcholine and N-methyl-D-aspartate
(NMDA) receptors are thought to play important roles
in the development of tinnitus. Disturbances of glutama-
tergic transmission have been implicated in various dis-
orders of the central nervous system (CNS) and also in
tinnitus [2]. These alterations may not only change the
balance between excitatory and inhibitory brain pro-
cesses in the auditory pathway, but are also likely to
involve other brain structures. NMDA-receptor-relayed
projections from the medial geniculate body to the lat-
eral nucleus of the amygdala are of particular impor-
tance in a pathophysiological model of tinnitus in which
connections between the auditory, limbic and autonomic
nervous system have been suggested as playing a crucial
part in the emergence of clinically relevant tinnitus [3].
The clinical observation that tinnitus sensation/percep-
tion - measured by pitch, maskability, and loudness -
does not correlate with tinnitus severity in patients suf-
fering from clinically important tinnitus [4-7] strongly
supports the thesis that brain structures other than the
auditory pathway must be involved.
In addition, NMDA receptor antagonists have been
reported to afford protection from hearing loss caused
by free-radical-induced damage to the hair cells [8].
The nicotinic acetylcholine receptor subunits a9 and
a10 also play a relevant role in the efferent auditory sys-
tem and the medial olivocochlear pathway [9,10]. Acti-
vation of a9a10 receptors inhibits mechanical
amplification brought about by the activity of outer hair
cells. As such, this nicotinic/cholinergic pathway could
be an interesting target for pharmacological intervention
in connection with impaired auditory processing [11,12].
In particular, patients suffering from chronic tinnitus
and sensorineural hearing loss may have an imbalance
in this system.
It is generally agreed that moderate-affinity, non-
competitive NMDA receptor antagonists combine good
efficacy and tolerability by preventing the pathological
activation of NMDA receptors, but allowing their phy-
siological activity [13]. Neramexane (1-amino-1,3,3,5,5-
pentamethylcyclohexane) is a new compound with a
dual mode of action, exhibiting antagonistic activity at
the a9a10 nicotinic acetylcholine receptor [14] and the
NMDA receptor [15]. Antagonistic properties at the
5-hydroytryptamin (5-HT3, serotonin) receptor [16] may
also contribute to its mechanism of action in tinnitus.
Neramexane was investigated for other indications in a
number of Phase II/III studies. Overall, neramexane was
safe and well tolerated in these studies.
So far, there are no well-established, specific medical
treatments for tinnitus that provide replicable reduction
of tinnitus and annoyance due to it [17]. The pharmaco-
logical effects of neramexane make it an interesting
compound that might interfere in a positive manner
with the pathophysiological processes involved in sub-
jective tinnitus. Therefore we performed a randomized,
double-blind, placebo-controlled clinical trial to assess
the effect of neramexane in patients with moderate to
severe tinnitus.
Methods
This Phase II clinical trial was conducted at 37 centers
in Austria and Germany as a randomized, placebo-
controlled, double-blind, parallel-group, four-arm, dose-
ranging study of neramexane in patients with moderate
to severe subjective tinnitus. The study was compliant
with the Declaration of Helsinki and was approved by
Health Authorities and Ethics Committees and regis-
tered as NCT00405886 at ClinicalTrials.gov.
Patients 18 to 65 years of age at screening with a clini-
cal diagnosis of persistent, subjective, moderate to
severe, uni- or bilateral tinnitus present for at least
3 months but not more than 18 months were included.
Diagnosis of these patients included a complete physical
and ear, nose and throat examination and also included
psychoacoustic measures and questionnaires including
the Tinnitus Interview. In order to differentiate and
characterize tinnitus patients in more detail, study reci-
pients were subjected to puretone audiometry, tinnitus
pitch and loudness matching and tinnitus masking. An
auscultation around the ear and neck to check for vas-
cular turbulences, inspection of the ear canal and the
tympanic membrane, observation for nystagmus and
tuning fork testing according to Weber and Rinne for
unilateral, conductive, or sensorineural hearing loss
were also performed.
Subjective tinnitus severity was graded using the
12-item German version (THI-12, German: TBF-12) of
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patient questionnaire [18] and the physician’s Clinical
Global Impression of Tinnitus Severity (CGI-S) scale.
Each question of the THI-12 can be answered by the
patient with either ‘often’ (2points), ‘sometimes’ (1
point) or ‘never’ (0 points) with a maximum total score
of 24 indicating most severe suffering from tinnitus. The
CGI-S asks physicians to rate their patients’ tinnitus
severity based on their past experience with other
patients with the same diagnosis and ranges from 1
(normal, not at all ill) to 7 (extremely ill). All patients
included in the study were considered to have moderate
to severe subjective tinnitus according to a THI-12 total
score ≥9 and a CGI-S score of ≥4 at both screening and
baseline. Patients had to have a body mass index (BMI)
≥18 kg/m
2 and ≤32 kg/m
2 and no clinically relevant
abnormalities following physical examination and
laboratory evaluation. Women of childbearing potential
were required to practice adequate contraception. All
patients provided written informed consent.
Patients were excluded if they presented with inter-
mittent or pulsatile tinnitus or tinnitus as a concomitant
symptom of another otological/neurological condition
(e.g. otitis media). Patients with conductive hearing
impairment were also excluded (air conduction thresh-
old >20 dB worse than bone conduction threshold in at
least two tested frequencies).
In addition, patients with epilepsy, acoustic neuroma,
multiple sclerosis, serious head/cervical trauma with
residual deficits, anamnestic HIV infection or any other
clinically relevant neurological or psychiatric disorder or
systemic disease (e.g. cardiac disease) following physical
examination or assessment of medical history were
excluded. Patients could not have received any other
concomitant pharmacologic or non-pharmacologic treat-
ment for tinnitus in the 28 days prior to screening (30
days if an investigational drug), including sound genera-
tors, counseling, behavioral therapy and psychotherapy.
Pregnant and breastfeeding women were excluded.
Patients who met the inclusion criteria and none of
the exclusion criteria were randomized to one of four
treatment groups: neramexane 25 milligrams per day
(mg/d), 50 mg/d or 75 mg/d or placebo. Treatment was
administered over a 16-week period consisting of a
4-week up-titration period and a 12-week fixed-dose
treatment period, with twice-daily dosing during both
treatment periods. In cases where the trial drug in the
50 or 75 mg/d group was poorly tolerated, the investiga-
tor could consider a dose reduction by 25 mg/d. These
cases received a reduced dosage throughout the trial, a
subsequent rechallenge to the randomly assigned, higher
dosage group was not allowed. After the treatment
phase, administration of study medication was ceased
immediately and patients were followed-up for further
four weeks with no active treatment and with restric-
tions on concomitant therapy. In total, this study
involved seven study visits: at screening, at baseline, and
at the end of Weeks 4, 8, 12, 16, and 20 (Figure 1).
The primary efficacy endpoint was the absolute
change in THI-12 total score from baseline to the end-
point visit (Visit 6, i.e. Week 16, or early termination).
The THI-12 is derived from the 25 item version of the
Tinnitus Handicap Inventory. The scale is easily admi-
nistered and is a psychometrically robust and reliable
tool to assess the different aspects of tinnitus suffering
[18]. Although initially validated in German language
only, it has meanwhile shown intercultural validation
[19] which makes it a suitable tool for further interna-
tional studies.
Secondary efficacy endpoints were the THI-12 total
score (absolute values and change from baseline) at all
further post-baseline visits, and the emotional-cognitive
and the functional-communicational subscores of the
THI-12 at all post-baseline visits. The results of a
patient’s self-assessment concerning tinnitus severity,
tinnitus annoyance, tinnitus impact on life, tinnitus as a
problem, hyperacusis as a problem, and hearing as a
problem were assessed during a structured tinnitus
interview and documented on 11-point Likert-like
scales. Absolute values of the scores of these items at all
visits as well as the changes from baseline were ana-
lyzed. Further criteria for assessment applied at all post-
baseline visits were the interview-based clinical global
impression of change (CGIC) and the total score and
depression and anxiety subscores of the HADS (German
version, HADS-D; [20]). The CGIC (item 27 of the tin-
nitus follow-up interview) was assessed by the patient
according to a 7-item Likert scale ranging from 1 (very
much improved or disappeared) to 7 (very much worse).
As depression and anxiety are common co-morbidities
in tinnitus patients, the HADS was used to monitor
both conditions in the study population. The HADS is a
reliable and validated questionnaire for non-psychiatrists
to assess symptoms of depression and anxiety in an out-
patient setting. In addition, the change in hearing-
threshold levels (dB) of the left and right ears, the
change in pitch match for the most troublesome tinni-
tus, the change in loudness match for the most trouble-
some tinnitus, and the change in minimum masking
levels were determined.
Measures of safety, assessed at defined times, included
standard clinical chemistry, coagulation, hematology and
urinalysis, physical and ear, nose and throat examina-
tion, vital signs, 12-lead electrocardiography (ECG),
urine drug screen and recording of spontaneously
reported adverse events. An independent safety monitor-
ing board continuously reviewed all serious adverse
events and adverse events leading to discontinuation.
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intention-to-treat (ITT) analysis set, i.e. all patients who
completed at least one post-baseline efficacy assessment
for THI-12 total score and who received at least one
dose of double-blinded study treatment. The change in
THI-12 total score from baseline to the endpoint visit
(i.e. Week 16 or early termination) was the primary effi-
cacy endpoint in this study. Analysis of covariance
(ANCOVA) with treatment group and center as factors
and THI-12 baseline value as covariate was used for
estimation of the treatment effects. The analysis was
performed using the last-observation-carried-forward
(LOCF) approach. Resulting p-values for pairwise treat-
ment comparison (each active dose versus placebo) were
evaluated for significance according to a hierarchical
step-down testing procedure for dose groups in order to
ensure an overall type I error of 5%. In addition, sensi-
tivity analyses were performed on the “treated-per-
protocol” population (TPP) and in an observed cases
analysis.
Secondary efficacy criteria were analyzed similarly in
an exploratory and descriptive manner (ITT and TPP).
Incidence rates of treatment-emergent and serious
adverse events, as well as events leading to discontinua-
tion or dose reduction, were calculated; MedDRA cod-
ing for adverse events was used. Vital signs, ECG data
and laboratory variables were analyzed by using descrip-
tive statistics and were screened for potentially clinically
significant values.
Patients were assigned to treatment groups in this multi-
center study according to a balanced randomization
procedure, using the RANCODE program (Version 3.6,
IDV; Gauting, Germany). The randomization schedule
and related relevant forms were kept sealed and locked in
the Department of Total Quality Management (TQM) at
Merz Pharmaceuticals GmbH and were not accessible
until termination of the study.
The study was conducted in a double-blind fashion.
The placebo tablets had the same appearance as nera-
mexane tablets. Neither the investigator, nor the other
medical staff, nor any patient knew the identity of any
individual study medication. All other persons involved
in the project (e.g. biostatisticians, data managers, moni-
tors) were maintained blinded throughout the study.
Members of the independent safety monitoring board
were unblinded where this was necessary for them to
perform a full case assessment.
Results
Patient disposition is summarized in Figure 2. Overall,
628 patients were screened from October 2005 to
March 2007, although 197 of these patients were
screened but not enrolled. The main reasons for screen-
ing failure included abnormal ECG, abnormal liver func-
tion, THI-12 score <9 and treatment with other
concomitant medication (e.g. benzodiazepines). In total,
431 patients were randomized to study treatment; 429
patients received double-blind treatment and were
included in the safety population (25 mg/d neramexane
group, 108; 50 mg/d group, 107; 75 mg/d group, 102;
placebo group, 112 patients). Two patients were rando-
mized but did not receive study treatment. A total of
4-week double-blind
uptitration period
4-week
screening period
4-week
follow-up period 12-week fixed-dose double-blind period
Start of treatment End of treatment
Start of study
Placebo
25 mg/d Neramexane (12.5 mg b.i.d.)
Week -4
75 mg/d Neramexane (37.5 mg b.i.d.)
50 mg/d Neramexane (25 mg b.i.d.)
End of study
Baseline
Randomization Week 16
Figure 1 Study flow chart.
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Page 4 of 10320 patients (74.6%) completed the study: 86 (77%) in
the placebo group, 89 (82%) in the 25 mg/d group, 81
(76%) in the 50 mg/d group and 64 (63%) in the 75 mg/
d group. The most frequent reason for discontinuation
in all treatment groups was adverse events (13%, 8%,
22% and 28% for the placebo, 25 mg/d, 50 mg/d, and 75
mg/d neramexane group, respectively). Of the 431 ran-
domized patients, 61 were excluded from the TPP popu-
lation due to major protocol violations, mainly owing to
their premature termination of study medication intake
or other non-compliance.
Baseline demographic and anamnestic data were com-
parable among the treatment groups (Table 1). More
than two thirds of patients in all treatment groups were
male, Caucasian and non-smokers. Most patients had
no or at most mild hearing loss. THI-12 total score at
baseline was similar between all treatment groups.
Audiometric and psychoacoustic outcomes for patients
         
     
N = 628 
Patients screened 
          
        
      
N = 197 
Screening failures 
         
        
     
N = 431 
Patients randomized 
          
        
      
N = 2 
Not treated 
         
        
    
N = 429 
Patients received study medication      
                
                              
N = 112 
Placebo 
N = 108 
25 mg/d 
Neramexane 
N = 107 
50 mg/d 
Neramexane 
N = 102 
75 mg/d 
Neramexane 
                                
                   
    
N = 26 
Withdrawn      
N = 19 
Withdrawn     
N = 26 
Withdrawn
N = 38 
Withdrawn
                                
         N = 86 
Active 
treatment 
(visit 6) 
completed 
N = 89 
Active 
treatment 
(visit 6) 
completed 
N = 81 
Active 
treatment 
(visit 6) 
completed 
N = 64 
Active 
treatment 
(visit 6) 
completed 
                                
       N = 0 
Drop-out 
after
visit 6 
N = 1 
Drop-out 
after
visit 6 
    
N = 3 
Drop-out 
after
visit 6 
N = 0 
Drop-out 
after
visit 6 
Figure 2 Patient disposition, flow chart.
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Page 5 of 10at baseline are shown in Table 2. The treatment groups
were comparable in terms of puretone thresholds, tinni-
tus pitch and loudness matching and minimum masking
level.
Figure 3 shows the course of the primary efficacy vari-
able from screening to Week 20. Reductions in the
THI-12 total score were observed in all treatment arms,
but were highest in the medium- and high-dose nera-
mexane groups. Comparison of changes between active
groups and placebo yielded no statistical significance at
the pre-defined endpoint, but a trend towards superior-
ity for neramexane 50 mg/d and 75 mg/d (estimated
treatment difference of 0.8 score points for 50 mg/d
neramexane, p = 0.098, and 0.5 score points for 75 mg/
d neramexane, p = 0.289). The 25 mg/d neramexane
group was not superior to placebo.
During the follow-up period, the effects increased
further for patients treated with 50 mg/d and 75 mg/d
neramexane and, despite decreasing sample size, a p-
value of 0.021 was found for the 50 mg group. The
results of sensitivity analyses investigating the ITT-OC
and the TPP population were consistent with the pri-
mary analysis (largest improvements for neramexane
50 mg/d group, estimated treatment differences 1.0 and
0.7 score points, respectively).
Table 3 summarizes the results of the main secondary
variables throughout the trial. Statistically superior
results of the patients treated with 50 mg/d neramexane
compared with placebo-treated patients were found in
the functional-communicational score of the THI-12.
P-values below 0.05 were also shown for two items of
the tinnitus interview, i.e. tinnitus annoyance and impact
on life on an 11-point scale. Remaining variables consis-
tently showed numerical superiority in the neramexane
50 mg/d group. No relevant changes were observed in
either treatment group for puretone threshold, tinnitus
pitch, loudness match, or minimum masking levels.
No relevant change of the HADS score was observed.
Decreases in the depression score (means ranging from
-1.6 for placebo to -2.4 for the 50 mg/d group) were
small and did not show a clear dose-dependency. This
supports the hypotheses that neramexane specifically
Table 1 Demographic and clinical characteristics at baseline (ITT population)
Placebo 25 mg/d Neramexane 50 mg/d Neramexane 75 mg/d Neramexane
N = 111 N = 106 N = 106 N =9 9
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age (years) 45.7 ± 12.2 45.7 ± 11.8 44.9 ± 12.1 46.2 ± 11.8
Height (m) 1.75 ± 0.10 1.77 ± 0.10 1.75 ± 0.10 1.76 ± 0.09
Weight (kg) 78.81 ± 13.64 80.14 ± 14.16 77.23 ± 13.55 78.45 ± 12.73
BMI (kg/m
2) 25.75 ± 3.33 25.48 ± 3.06 25.16 ± 3.21 25.29 ± 3.04
Mean tinnitus duration (months) 9.4 ± 4.64 9.5 ± 4.65 9.1 ± 4.17 8.8 ± 4.08
THI-12 at baseline 14.4 ± 3.7 14.4 ± 3.9 14.5 ± 3.3 13.9 ± 3.7
n % n % n % n %
Sex
Male 76 68.5 75 70.8 72 67.9 68 68.7
Female 35 31.5 31 29.2 34 32.1 31 31.3
Ethnic origin
Caucasian 109 98.2 105 99.1 105 99.1 98 99.0
Asian 0 0.0 0 0.0 1 0.9 1 1.0
Oriental 1 0.9 1 0.9 0 0.0 0 0.0
Other 1 0.9 0 0.0 0 0.0 0 0.0
Smoking habit
Non-smoker 66 59.5 61 57.5 67 63.2 68 68.7
Smoker 27 24.3 22 20.8 19 17.9 17 17.2
Ex-smoker 18 16.2 23 21.7 20 18.9 14 14.1
Hearing loss (hearing threshold level)
None (<20 dB) 64 57.7 65 61.3 61 57.5 61 61.6
Mild (20-40 dB) 42 37.8 33 31,1 43 40.6 30 30.3
Moderate (>40-70 dB) 5 4.5 8 7.5 1 0.9 5 5.1
Severe (>70-95 dB) 0 0.0 0 0.0 1 0.9 3 3.0
ITT = intent-to-treat, N = number of patients in specified group, n = number of patients,
SD = standard deviation.
Calculation of percentages based on N.
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Page 6 of 10improves tinnitus symptoms and does not act through
an antidepressant or anxiolytic effect. Patients without
symptoms of anxiety or depression (HADS anxiety or
HADS depression subscore < 10) benefited from nera-
mexane treatment, whereas subjects with symptoms of
anxiety or depression did not benefit. The estimated
treatment difference for patients in the 50 mg dose
group with a baseline depression subscore < 10 was 1.2
score points on the THI-12 (p = 0.022) and 1.3 score
points (p = 0.030) for those patients with a baseline
anxiety subscore < 10.
The most frequent adverse events are summarized in
Table 4. The overall percentages of patients reporting at
least one treatment-emergent adverse event, whether
related to the study medication or not, were almost
comparable between treatment groups. The lowest rate
of adverse events (AEs) was observed in the 25 mg/d
neramexane group (59.3%) followed by the placebo
group (70.5%), the 50 mg/d neramexane group (73.8%)
and finally the 75 mg/d neramexane group (78.4%).
The percentages of patients who reported dizziness
were similar in the placebo (8.0%) and 25 mg/d nera-
mexane groups (10.2%) but increased with higher nera-
mexane doses up to 37.3% in the 75 mg/d neramexane
group. The incidence of vertigo also increased dose-
dependently from the placebo to the high-dose nera-
mexane group. The incidence of fatigue was higher in
the 50 mg/d and 75 mg/d neramexane groups than in
the other two treatment groups, but no clear dose-
dependence was evident.
As shown in Table 5, the percentage of patients with
treatment-emergent adverse events leading to dose
reduction increased with neramexane dose. Dizziness,
vertigo, nausea and fatigue were the most common trea-
ted-emergent adverse events leading to dose reduction.
There was no relevant influence of the study medica-
tion on laboratory values, ECG or vital signs. No clini-
cally meaningful changes in hematology, clinical
chemistry or coagulation values were apparent from
screening to week 8 or week 16 (or early termination) in
any of the treatment groups. For the vast majority of
patients, the ECG was assessed as normal. Furthermore,
none of the abnormalities assessed as clinically relevant
by the investigator fulfilled the criteria for potentially
clinically significant PR, QRS or QTcB intervals. Mean
and median values of blood pressure, pulse rate and
weight were similar across all treatment groups and
were stable throughout the study.
Discussion
The primary objective of this study was to compare the
efficacy, tolerability and safety of three different
Table 2 Audiometric and psychoacoustic characteristics
of patients at screening (ITT population)
N Mean ± SD
Puretone audiometry (worst ear)
Hearing threshold [dB]
Placebo 111 19.9 ± 10.6
Neramexane 25 mg/d 106 20.1 ± 12.6
Neramexane 50 mg/d 106 19.4 ± 10.6
Neramexane 75 mg/d 99 20.6 ± 14.7
High frequency hearing threshold [dB]
Placebo 111 36.9 ± 20.2
Neramexane 25 mg/d 106 36.0 ± 21.4
Neramexane 50 mg/d 106 36.6 ± 21.7
Neramexane 75 mg/d 99 36.9 ± 19.9
Tinnitus matching (worst ear)
Frequency (pitch) match [Hz]
Placebo 109 4577.5 ± 2601.9
Neramexane 25 mg/d 105 4915.1 ± 2596.2
Neramexane 50 mg/d 103 4958.7 ± 2683.1
Neramexane 75 mg/d 97 4920.9 ± 2804.8
Loudness match [dB]
Placebo 105 38.6 ± 19.3
Neramexane 25 mg/d 103 40.5 ± 20.5
Neramexane 50 mg/d 99 39.3 ± 20.3
Neramexane 75 mg/d 91 39.2 ± 18.5
Minimal masking level (worst ear)
Masking level [dB]
Placebo 106 44.8 ± 21.0
Neramexane 25 mg/d 100 46.8 ± 19.0
Neramexane 50 mg/d 99 44.8 ± 21.1
Neramexane 75 mg/d 92 44.2 ± 20.6
ITT = intent-to-treat, N = number of patients, SD = standard deviation.
0
Week 4 Week 12
12.0 ± 3.6
11.2 ± 4.1
Week 16
Endpoint 
End of Treatment
Baseline Follow-up
Placebo
25mg NER
50mg NER
75mg NER
Week 8
10
11
12
13
14
15
Mean THI-12 score1
-3.33
- 0.8 pts2
p = 0.098
-1 . 3p t s 2
p = 0.021
Figure 3 Mean course of the primary efficacy variable (THI-12
score) 1. Intention-to-treat, last observation carried forward. 2.
Difference of least square means 50 mg vs. placebo and p-values
from ANCOVA with treatment and center as factor, baseline as
covariate 3. Difference from baseline, * p < 0.05.
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Page 7 of 10neramexane mesylate dosages (25, 50 and 75 mg/d) with
placebo in patients with subjective tinnitus after a 16-
week double-blind treatment period. Although statisti-
cally significant differences on the THI-12 total scale in
Week 16 were not shown for any of the neramexane
groups as compared with placebo, the study results
nevertheless highlight the need for further investigation
of neramexane as a possible treatment for patients with
moderate to severe tinnitus.
During the initial 8 weeks of treatment, all patients,
irrespective of their treatment, showed a distinct
improvement of their tinnitus as measured by the THI-
12 score. Thereafter, the THI-12 score further decreased
solely in patients treated with the higher dosages of ner-
amexane (50 and 75 mg/d), whereas placebo-treated
patients and patients receiving the low dosage of nera-
mexane (25 mg/d) showed no further improvement. It
seems that the placebo effect abates or even ends after
8 weeks.
An interesting aspect of the trial is that, even after dis-
continuation of treatment, further improvement of the
tinnitus symptoms occurred, resulting in statistically
significant treatment differences for the neramexane
50 mg/d group in Week 20, which was 4 weeks after
termination of the study medication (Figure 3). As the
elimination half-life of neramexane is 30-45 hours, this
further improvement is very unlikely to be attributable
to a direct effect of the substance. As only one post-
treatment measurement was performed in this study,
this post-treatment effect is further investigated in an
ongoing Phase 3 trial.
Measuring a purely subjective symptom is always a
difficult clinical problem. Although the tinnitus ques-
tionnaire used is regarded as accurate and reliable [18]
it is of great importance that further secondary results,
measured in different ways, show consistent results. The
measurement of tinnitus annoyance and tinnitus’ impact
on life by numerical or visual analog scales are com-
monly used instruments to assess tinnitus, and are
recommended e.g. in the guidelines of the German Tin-
nitus Society [21].
There was no separation of dose groups in the audio-
metric and psychoacoustic measurements, including tin-
nitus masking and matching of frequency and loudness.
Table 3 Summary of main secondary variables at week 16 (end of treatment); intention to treat and LOCF analysis
Variable (range) Placebo
(N = 111)
25 mg/d Neramexane
(N = 106)
50 mg/d Neramexane
(N = 106)
75 mg/d Neramexane
(N = 99)
THI-12 Emotional-cognitive subscore (0-14) -1.7 ± 2.45 -1.2 ± 2.50 0.145 -2.0 ± 2.64 0.388 -1.8 ± 2.59 0.645
THI-12 Functional-communicational
subscore
(0-10) -0.7 ± 1.75 -0.7 ± 1.47 0.859 -1.2 ± 1.96 0.021* -1.1 ± 1.77 0.097
Tinnitus loudness/severity (0-10) -0.7 ± 1.64 -0.4 ± 1.51 0.279 -0.9 ± 2.05 0.212 -0.9 ± 1.56 0.233
Tinnitus annoyance (0-10) -0.8 ± 2.04 -0.8 ± 1.95 0.639 -1.3 ± 2.26 0.043* -0.8 ± 1.85 0.494
Tinnitus impact on life (0-10) -1.0 ± 1.98 -0.6 ± 1.89 0.335 -1.4 ± 2.61 0.038* -0.8 ± 2.04 0.924
Tinnitus as a problem (0-10) -1.1 ± 1.86 -0.6 ± 1.72 0.058 -1.3 ± 2.42 0.328 -0.9 ± 2.05 0.951
Hyperacusis as a problem (0-10) -0.7 ± 2.51 -0.5 ± 2.49 0.271 -0.8 ± 2.72 0.778 -0.8 ± 1.85 0.666
Hearing as a problem (0-10) -0.2 ± 1.65 -0.0 ± 2.01 0.782 -0.7 ± 1.89 0.088 -0.1 ± 1.86 0.863
CGIC % improvement 27.9 22.6 34.0 38.4
Mean ± SD and p-values for changes, * p < 0.05 favoring treatment
(ANCOVA with treatment and center as factor, baseline as covariate).
Negative values indicate improvements.
Table 4 Frequency of patients with treatment-emergent adverse events by preferred term (safety population),
incidence >5% in any treatment group
Preferred term (MedDRA 9.1) Placebo
(N = 112)
25 mg/d Neramexane
(N = 108)
50 mg/d Neramexane
(N = 107)
75 mg/d Neramexane
(N = 102)
n % n % n % n %
Any adverse event 79 70.5 64 59.3 79 73.8 80 78.4
Dizziness 9 8.0 11 10.2 21 19.6 38 37.3
Headache 15 13.4 11 10.2 14 13.1 11 10.8
Vertigo 1 0.9 3 2.8 10 9.3 11 10.8
Fatigue 3 2.7 4 3.7 9 8.4 8 7.8
Hypertension 3 2.7 1 0.9 3 2.8 6 5.9
Nasopharyngitis 9 8.0 7 6.5 6 5.6 6 5.9
Nausea 5 4.5 7 6.5 5 4.7 5 4.9
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that the tinnitus suffering as perceived is not systemati-
cally dependent on audiometrically derived measures of
tinnitus loudness and pitch [4-7]. A large number of
patients with chronic and sub-chronic tinnitus are not
bothered by its appearance. The disease is not character-
ized by the loudness of the sound but the inability of a
patient to cope with this sound [22]. As such, validated
Patient-Reported Outcome (PRO) questionnaires are
more useful in assessing the suffering or nuisance level
caused, and the patient’s ability to cope with chronic
tinnitus [23].
Neramexane was well tolerated, and no new safety
concerns were raised by any of the observations made
in this study. Neither laboratory values, nor ECG data,
nor vital signs showed any important influence of the
study medication. Overall, the incidence of adverse
events (mainly dizziness, vertigo, and fatigue) increased
with higher neramexane doses. Frequencies of AEs
other than the three mentioned above showed no dose-
relationship. Dizziness was a main reason for premature
discontinuation in the medium- and high-dose group.
A placebo-controlled crossover study with memantine,
an NMDA antagonist with moderate affinity, did not
show a significant difference between memantine and
placebo treatment on tinnitus suffering as assessed with
the 25-item version of the THI [24]. However, as the
authors conclude, the study had some methodological
weaknesses (dose limitation, duration of wash-out
phase) and the negative results do not generally exclude
the usefulness of substances with NMDA antagonistic
properties for the treatment of tinnitus.
Conclusions
This proof-of-concept and dose-finding study demon-
strated the safety and tolerability of neramexane treat-
ment in patients with moderate to severe tinnitus
receiving no concomitant tinnitus therapy. On the basis
of the study results, the 50 mg/d neramexane mesylate
dose is concluded to be the appropriate standard dose
for further clinical development. In order to confirm
this hypothesis, an international Phase III clinical trial
program has now been started.
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